Scilex Holding Company stock analysis
Scilex Holding Company (SCLX) Stock Price & Analysis
SCLX Stock Chart & Stats
- Day’s Range
- $1.40 - $1.57
- 52-Week Range
- $1.40 - $27.00
- Previous Close
- $1.56
- Volume
- N/A
- Average Volume (3M)
- 44.40K
- Market Cap
- $10.06M
- Enterprise Value
- $161.94T
- Total Cash (Recent Filing)
- $581.00K
- Total Debt (Recent Filing)
- $95.56M
- Price to Earnings (P/E)
- ―
- Beta
- 0.82
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
SCLX FAQ
What was Scilex Holding Company’s price range in the past 12 months?
What is Scilex Holding Company’s market cap?
When is Scilex Holding Company’s upcoming earnings report date?
Is Scilex Holding Company overvalued?
Does Scilex Holding Company pay dividends?
What is Scilex Holding Company’s EPS estimate?
How many shares outstanding does Scilex Holding Company have?
Which hedge fund is a major shareholder of Scilex Holding Company?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Scilex Holding Company
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Henry H. Ji
- Employees
- 34
- Website
- www.scilexholding.com
- Address
- 960 San Antonio Road, Palo Alto, CA, 94303, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 0 | 17 |
| Technical Analysis | 5 | 0 | 5 |
| Moving Averages | 0 | 0 | 12 |














